Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Other Working Capital Changes (2021 - 2025)

Historic Other Working Capital Changes for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $1.4 million.

  • Krystal Biotech's Other Working Capital Changes rose 35839.69% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year increase of 25948.19%. This contributed to the annual value of $8.9 million for FY2024, which is 45266.75% up from last year.
  • Krystal Biotech's Other Working Capital Changes amounted to $1.4 million in Q3 2025, which was up 35839.69% from -$19000.0 recorded in Q2 2025.
  • Krystal Biotech's Other Working Capital Changes' 5-year high stood at $6.9 million during Q4 2024, with a 5-year trough of -$1.3 million in Q1 2021.
  • For the 5-year period, Krystal Biotech's Other Working Capital Changes averaged around $849368.4, with its median value being $126000.0 (2023).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first surged by 196785.71% in 2023, then plummeted by 28888.89% in 2024.
  • Krystal Biotech's Other Working Capital Changes (Quarter) stood at $1.7 million in 2021, then decreased by 4.8% to $1.6 million in 2022, then plummeted by 30.26% to $1.1 million in 2023, then surged by 503.66% to $6.9 million in 2024, then crashed by 80.46% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, -$19000.0 for Q2 2025, and $3.0 million during Q1 2025.